Piramal Pharma Share Price Tumbles After Q1 Loss – Is There Hope Ahead in 2025?
Piramal Pharma Ltd. (PPLPHARMA) shares came under selling pressure on July 29, 2025, after the company reported a disappointing set of numbers for the June quarter. The stock fell by 3.35% to ₹197.50 on the NSE, triggering concern among investors who have already witnessed the stock erode nearly 33% from its 52-week high of ₹304.
The June quarter saw the company swing into a net loss of ₹81.7 crore, a sharp reversal from the ₹153.5 crore profit posted in the March quarter. This is not the first loss the company has reported — it had recorded a net loss in the same quarter last year as well. The pressure in the business was visible not just in the bottom line, but across key operating metrics, which makes this quarter particularly concerning for long-term investors following Piramal Pharma’s share price closely.
Revenue and Profitability Under Strain
The company’s revenue came in at ₹1,933.71 crore, down 1% year-on-year and nearly 30% lower on a sequential basis. EBITDA, which reflects core operating profitability, nearly halved from last year to ₹106.7 crore. More worryingly, EBITDA margins crashed to 5.5% from 10.5% a year ago and 26.9% in the March 2025 quarter. This rapid margin contraction reflects both pricing pressure and operational inefficiencies across divisions.
Despite the setbacks, Piramal Pharma has reiterated confidence in its long-term vision to reach $2 billion in revenue with a 25% margin by FY2030. But for now, short-term pain seems inevitable, and it’s showing up clearly in the stock performance and investor sentiment.
Segment-Wise Breakdown: Some Bright Spots
The company’s CDMO (contract development and manufacturing organisation) business, which is a major revenue contributor, declined 6% year-on-year to ₹997 crore. This was primarily due to destocking in a large on-patent commercial product. However, excluding this one-off impact, the management stated that the CDMO business actually posted mid-teen revenue growth, especially from overseas facilities where margins also improved.
Meanwhile, the complex hospital generics business grew modestly by 1% year-on-year to ₹637 crore. The company attributed this to the phasing of institutional orders, suggesting that this segment may pick up momentum in the coming quarters.
The consumer healthcare division turned out to be a silver lining, with a strong 15% year-on-year growth to ₹302 crore. Power brands within this segment registered 18% growth and now contribute nearly half (49%) of the consumer healthcare revenue — a positive sign for brand-led future expansion.
Technical View: Key Levels to Watch for PPLPHARMA
From a technical standpoint, Piramal Pharma shares are facing stiff resistance near ₹202.34 and ₹204.95, as indicated by Fibonacci pivot levels. The nearest supports are at ₹193.31, ₹187.73, and if selling intensifies, the stock could test ₹178.69 in the near term. The Relative Strength Index (RSI 14) has dropped to 39.34, indicating that the stock is approaching oversold territory.
Volumes on the chart remain moderate with no major accumulation observed yet. The stock is trading below its 20-day EMA, suggesting ongoing bearish sentiment. Unless the share price closes above ₹211.38 with strong volume, upward momentum may be hard to sustain in the short term.
Investor Sentiment and Market Reaction
Even though the company continues to project long-term growth optimism, the current financial weakness has rattled the market. Shares ended 1.1% higher at ₹204.5 on Monday, ahead of the results, but the sentiment reversed swiftly on Tuesday after the earnings miss. The broader indices — SENSEX and NIFTY — also remained muted, adding to the stock-specific pressure.
Investors searching for piramal pharma share price updates and analyzing ppl pharma stock trends will need to focus closely on future earnings consistency, margin improvements, and stabilization of the CDMO business. Moreover, the company's outlook in the Nifty 500 index and its small-cap status add a layer of volatility that retail investors should be mindful of.
Is Piramal Pharma a Value Buy After the Correction?
While the correction in share price may seem like a value opportunity, the stock still lacks strong fundamental triggers in the near term. Long-term investors may consider accumulating gradually if the price holds support around ₹190, but only with a long horizon and high-risk tolerance.
The company's ambitious FY2030 plan is certainly promising, but investors will look for consistent quarterly improvements before regaining confidence. In the interim, any positive updates on institutional orders, margin recovery, or global CDMO growth could serve as upside catalysts.
As of the latest trade, Piramal Pharma share price is hovering at ₹197.50. The market will closely watch upcoming commentary from the management and quarterly improvements to determine the future trajectory of this stock.
Stay connected with Bazaar Updates for real-time Piramal Pharma news, chart analysis, and insights into trending stocks in the pharma sector.
Join WhatsApp Group
